CA-4948 NEW
| Price | $30 | $70 | $89 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-04-29 |
Product Details
| Product Name: CA-4948 | CAS No.: 1801344-14-8 |
| Purity: 99.62% | Supply Ability: 10g |
| Release date: 2025/04/29 |
Product Introduction
Bioactivity
| Name | CA-4948 |
| Description | CA-4948 (Emavusertib) is a potent IRAK4/FLT3 inhibtor. CA-4948 with anti-tumor activity. |
| In vitro | CA-4948, demonstrated good cellular activity in ABC DLBCL and AML cell lines.?Inhibition of TLR signaling leading to decreased IL-6 levels was also observed in whole blood assays.?CA-4948 demonstrated moderate to high selectivity in a panel of 329 kinases as well as exhibited desirable ADME and PK profiles including good oral bioavailability in mice, rat, and dog and showed >90% tumor growth inhibition in relevant tumor models with excellent correlation with in vivo PD modulation.?CA-4948 was well tolerated in toxicity studies in both mouse and dog at efficacious exposure.?The overall profile of CA-4948 prompted us to select it as a clinical candidate for evaluation in patients with relapsed or refractory hematologic malignancies including non-Hodgkin lymphoma and acute myeloid leukemia[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : < 0.1 mg/mL (insoluble) DMSO : 27.78 mg/mL (56.52 mM), Sonication is recommended. |
| Keywords | Toll | rheumatoid | Myd88 | lymphoma | IRAK4 | IRAK | Interleukin-1 receptor associated kinase | Inhibitor | inhibit | inflammation | IL-1R associated kinase | IL-1R | Fms like tyrosine kinase 3 | FLT3 | Cluster of differentiation antigen 135 | CD135 | CA-4948 | CA4948 | CA 4948 | arthritis |
| Inhibitors Related | UNC2025 | Gilteritinib | Nintedanib | Sunitinib Malate | Sorafenib | Tandutinib | ANTHRAQUINONE-2-CARBOXYLIC ACID | Pexidartinib | Thalidomide 4-fluoride | Sorafenib tosylate | Ginsenoside Rb1 | Fedratinib |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/100MG |
Hubei Chuchang Biotech Co., Ltd.
|
2024-04-17 | ||
| $0.00/25Kg/Bag |
Sinoway Industrial co., ltd.
|
2022-07-19 | ||
| $0.00/1KG |
VIP4Y
|
Qingdao Truelight functional Material Technology Co., Ltd.
|
2021-11-22 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY